Firms
Theme

DPRO

Draganfly Inc. · NASDAQ

News

7 latest

Zacks Investment Research

DPRO Expands Defense Autonomy Capabilities Through Strategic Investment

Draganfly (DPRO) announced a strategic investment in DoD Solution, an Estonian-Ukrainian defense technology company, to expand its drone autonomy capabilities. The investment provides access to AURA AI technology for autonomous navigation, target tracking, and guidance in GPS-denied environments. Successful integration could strengthen Draganfly's competitive positioning in the defense market and create opportunities for longer-term growth and commercial agreements.

Zacks Investment Research

Can Draganfly Turn Medical Drone Delivery Into a Growth Opportunity?

Draganfly (DPRO) has completed initial proof-of-concept flights for its medical drone delivery pilot with Mass General Brigham in Boston, targeting healthcare logistics and emergency response applications. The company trades at a valuation discount (1X forward P/S vs. industry 2.10X) but shares have declined 28% in six months, and the stock carries a Zacks Rank #5 (Strong Sell) rating.

Zacks Investment Research

New Strong Sell Stocks for October 9th

Zacks has added three stocks to its Strong Sell list: Accendra Health (ACH), Ardelyx (ARDX), and Draganfly (DPRO). All three companies have experienced significant downward revisions to their earnings estimates over the past 60 days, with ACH seeing a 109.4% downward revision, ARDX a 25% revision, and DPRO a 59.6% revision.

GlobeNewswire Inc.

Draganfly Announces Closing of US$10 Million Strategic Investment

Draganfly Inc. (NASDAQ: DPRO) closed a registered direct offering of 1,869,159 common shares at US$5.35 per share, raising approximately US$10 million in gross proceeds. The company plans to use the net proceeds to accelerate development of advanced strategic capabilities and fund general working capital to meet demand in U.S. and international markets. Jett Capital Advisors and Northland Capital Markets served as joint-lead placement agents.

Mentions DPRO

Zacks Investment Research

Lockheed Martin (LMT) Beats Q3 Earnings and Revenue Estimates

Lockheed Martin reported Q3 2026 earnings of $7.97 per share, beating consensus estimates of $7.49, with revenues of $20.71 billion exceeding expectations. The company has outperformed the S&P 500 by 14% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

GE Aerospace (GE) Q3 Earnings and Revenues Top Estimates

GE Aerospace reported Q3 2026 earnings of $2.25 per share, beating consensus estimates of $2.02 and representing an 11.39% surprise. Revenue reached $13.29 billion, surpassing estimates by 4.99%.

Zacks Investment Research

Motorola Boosts Counter-Drone Security Footprint With D-Fend Buyout

Motorola Solutions has acquired D-Fend Solutions for $1.5 billion to expand its counter-drone security offerings. D-Fend's EnforceAir platform uses radio-frequency cyber-takeover technology to safely neutralize unauthorized drones without disrupting authorized operations or communications. The acquisition complements Motorola's existing unmanned systems ecosystem and is expected to be modestly accretive to earnings by 2027.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $DPRO · 0 threads

Sign in to post on $DPRO

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev